Surgical Procedures for Reducing Ovarian Cancer Risk (SOROCk Trial)
Trial Summary
The trial protocol does not specify whether you need to stop taking your current medications. However, if you are on cytotoxic chemotherapy, you must not have received it within the past 30 days to be eligible.
Risk-reducing bilateral salpingo-oophorectomy (RRSO) has been shown to reduce ovarian cancer deaths in high-risk women, particularly those with BRCA1/2 mutations. However, the effectiveness of bilateral salpingectomy alone in reducing ovarian cancer risk remains unclear, though it is being studied for its safety and acceptability.
12345Studies suggest that procedures like bilateral salpingectomy and salpingo-oophorectomy are generally safe, but they can lead to early menopause and hormone deficiency, which have their own risks. Some women may also develop a rare cancer called primary peritoneal carcinomatosis after the surgery.
12367Bilateral Salpingectomy with Oophorectomy is unique because it involves the removal of both fallopian tubes and sometimes the ovaries to reduce ovarian cancer risk, especially in women with genetic predispositions. This approach is different from other treatments as it is often performed opportunistically during other surgeries like hysterectomy or sterilization, and it aims to prevent cancer by removing tissues where cancer often starts.
15689Eligibility Criteria
This trial is for women aged 35-50 with a BRCA1 mutation, who are considering or have deferred risk-reducing surgery of the fallopian tubes and ovaries. They must be medically fit for surgery, not currently have ovarian cancer, and understand they can't naturally conceive post-surgery.Inclusion Criteria
Exclusion Criteria
Participant Groups
- Prevention of ovarian cancer
- Specifically high-grade serous carcinoma (HGSC)
- Prevention of ovarian cancer
- Specifically high-grade serous carcinoma (HGSC)
- Prevention of ovarian cancer
- Specifically high-grade serous carcinoma (HGSC)